Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer-Reference-Cited by-同舟云学术

Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer

Published:2021-06-14 Issue: Volume: Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Khan Kabir A¹²^ORCID,Wu Florence TH¹²^ORCID,Cruz‐Munoz William¹²,Kerbel Robert S¹²^ORCID

Affiliation:

1. Department of Medical Biophysics University of Toronto Toronto ON Canada

2. Biological Sciences Platform Sunnybrook Research Institute Toronto ON Canada

Funder

Canadian Institutes of Health Research

Canadian Cancer Society

Worldwide Cancer Research

University of Toronto

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201708253

Reference182 articles.

1. Tumor cell‐derived angiopoietin‐2 promotes metastasis in melanoma;Abdul Pari AA;Cancer Res,2020

2. Abstract 4492: Blockade of angiopoietin‐2 or Tie2 is equally effective at inhibiting tumor growth and reducing tumor vessel density in most human tumor xenograft models;Adler AP;Cancer Res,2014

3. Bevacizumab in stage II‐III colon cancer: 5‐year update of the National Surgical Adjuvant Breast and Bowel Project C‐08 trial;Allegra CJ;J Clin Oncol,2013

4. Combined antiangiogenic and anti–PD‐L1 therapy stimulates tumor immunity through HEV formation;Allen E;Sci Transl Med,2017

5. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer;Al Wadi K;Expert Opin Pharmacother,2016

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Angiogenic Factors on the Epithelial-to-Mesenchymal Transition and Their Impact on the Onset and Progression of Oral Squamous Cell Carcinoma: An Overview;Cells;2024-07-31

2. Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma;Journal of Experimental & Clinical Cancer Research;2024-07-29

3. Milestones in tumor vascularization and its therapeutic targeting;Nature Cancer;2024-06-25

4. Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials;Nature Reviews Clinical Oncology;2024-04-10

5. The role of vasculature and angiogenesis in respiratory diseases;Angiogenesis;2024-04-05